Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CAOCCI, Giovanni
CarPAs, NCT04709731 / 2018-001334-18: Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia	Not yet recruiting	2	50	Europe	Ponatinib 15mg QD, ICLUSIG, AP24534, Ponatinib 30mg QD	Associazione Italiana Pazienti Leucemia Mieloide Cronica	Chronic Myeloid Leukemia (CML)	10/24	04/25
PV-ARC, NCT06134102: Clinical and Laboratory Characteristics of Polycythemia Vera	Completed	N/A	1150	Europe		IRCCS Azienda Ospedaliero-Universitaria di Bologna	Polycythemia Vera	12/23	12/23
TFR-PRO, NCT04621851: Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation	Recruiting	N/A	3000	Europe, Canada		University of Milano Bicocca	Chronic Myeloid Leukemia	09/21	09/23
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera	Recruiting	N/A	1055	Europe		IRCCS Azienda Ospedaliero-Universitaria di Bologna	Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis	05/32	05/32
PHOENICS, NCT06119269: Ponatinib in CML Patients in Chronic Phase	Recruiting	N/A	100	Europe	Therapeutic drug monitoring, Molecular Response	University of Pisa	Chronic Myeloid Leukemia, Chronic Phase	01/24	12/24